Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Lumefantrine
Accession Number
DB06708
Type
Small Molecule
Groups
Approved
Description

Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.

Structure
Thumb
Synonyms
  • (±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
  • 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
  • 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
  • Benflumetol
  • dl-Benflumelol
  • Lumefantrine
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CoartemLumefantrine (120 mg/1) + Artemether (20 mg/1)TabletOralNovartis Pharmaceuticals Corporation2009-04-07Not applicableUs00078 0568 45 nlmimage10 6c443641
CoartemLumefantrine (120 mg/1) + Artemether (20 mg/1)TabletOralDepartment Of State Health Services, Pharmacy Branch2009-04-072018-02-28Us
CoartemLumefantrine (120 mg/1) + Artemether (20 mg/1)TabletOralCentral Texas Community Health Centers2009-04-07Not applicableUs
Categories
UNII
F38R0JR742
CAS number
82186-77-4
Weight
Average: 528.94
Monoisotopic: 527.154947772
Chemical Formula
C30H32Cl3NO
InChI Key
DYLGFOYVTXJFJP-MYYYXRDXSA-N
InChI
InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
IUPAC Name
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol
SMILES
CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1

Pharmacology

Indication

Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.

Associated Conditions
Pharmacodynamics

Lumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. It is thought that administration of lumefantrine with artemether results in cooperate antimalarial clearing effects. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thus thought to provide rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.

Mechanism of action

The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Food increases absorption.

Volume of distribution
Not Available
Protein binding

99.7% bound

Metabolism

Extensively metabolized in the liver primarily by cytochrome P450 3A4. The major metabolite found in plasma is desbutyl-lumefantrine.

Route of elimination
Not Available
Half life

~ 4.5 days

Clearance
Not Available
Toxicity

Common side effects of combination artemether/lumefantrine therapy in adults include headache, anorexia, dizziness, and asthenia. Common side effects in children include pyrexia, cough, vomiting, anorexia, and headache. Possible serious adverse effects include QT prolongation, bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 9%; children, 6%), hypersensitivty reaction, and angioedema.

Affected organisms
  • Plasmodium
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Lumefantrine.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Lumefantrine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Lumefantrine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lumefantrine.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Lumefantrine.
9-aminocamptothecinThe metabolism of 9-aminocamptothecin can be increased when combined with Lumefantrine.
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Lumefantrine.
AcebutololThe metabolism of Lumefantrine can be decreased when combined with Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Lumefantrine.
AcepromazineThe risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Acepromazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of lumefantrine and artemether.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015653
KEGG Drug
D03821
PubChem Compound
6437380
PubChem Substance
99443260
ChemSpider
4941944
BindingDB
50123012
ChEBI
156095
ChEMBL
CHEMBL38827
PharmGKB
PA165111722
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lumefantrine
ATC Codes
P01BF01 — Artemether and lumefantrine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionPlasmodium Infections2
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
1CompletedOtherHealthy Volunteers / Plasmodium Infections1
1CompletedPreventionPlasmodium Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Plasmodium Infections1
1CompletedTreatmentMalaria caused by Plasmodium falciparum1
1CompletedTreatmentMalaria caused by plasmodium vivax1
1Not Yet RecruitingTreatmentDrug Combination / Healthy Volunteers / Pharmacokinetics1
1, 2CompletedTreatmentPlasmodium Infections1
1, 2TerminatedTreatmentDrug Combination / Healthy Volunteers / Pharmacokinetics1
2Active Not RecruitingTreatmentPlasmodium Infections1
2Not Yet RecruitingTreatmentMalaria caused by plasmodium vivax1
2Not Yet RecruitingTreatmentPlasmodium Infections1
2RecruitingTreatmentAcute Uncomplicated Plasmodium Falciparum Malaria1
2RecruitingTreatmentPlasmodium Infections2
2TerminatedTreatmentPlasmodium Infections1
2, 3CompletedTreatmentAsymptomatic Malaria / Plasmodium Falciparum / Plasmodium Infections1
2, 3CompletedTreatmentMalaria caused by Plasmodium falciparum1
2, 3CompletedTreatmentPlasmodium Infections1
2, 3CompletedTreatmentAcute, uncomplicated Falciparum Malaria1
2, 3RecruitingTreatmentUncomplicated Falciparum Malaria1
3Active Not RecruitingTreatmentPlasmodium Infections1
3CompletedPreventionPlasmodium Infections1
3CompletedTreatmentDrug Resistant Malaria Due to Plasmodium Falciparum1
3CompletedTreatmentFalciparum / Plasmodium Infections1
3CompletedTreatmentFevers / Plasmodium Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
3CompletedTreatmentMalaria caused by Plasmodium falciparum / Plasmodium Infections1
3CompletedTreatmentMalaria caused by plasmodium vivax1
3CompletedTreatmentMalaria in Pregnancy1
3CompletedTreatmentP. Falciparum Malaria1
3CompletedTreatmentPlasmodium Falciparum Infection1
3CompletedTreatmentPlasmodium Falciparum Malaria2
3CompletedTreatmentPlasmodium Infections13
3CompletedTreatmentUncomplicated Knowlesi Malaria1
3Not Yet RecruitingTreatmentPlasmodium Falciparum Malaria (Uncomplicated)2
3RecruitingTreatmentPlasmodium Falciparum1
3RecruitingTreatmentPlasmodium Vivax Malaria Without Complication1
3Unknown StatusTreatmentPlasmodium Infections1
3Unknown StatusTreatmentUncomplicated Malaria1
4CompletedNot AvailablePlasmodium Infections1
4CompletedNot AvailableUncomplicated Malaria1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
4CompletedBasic SciencePlasmodium Falciparum Clinical Episode / Plasmodium Falciparum Infection / Plasmodium Vivax Clinical Episode / Plasmodium Vivax Infection1
4CompletedHealth Services ResearchAnemias / Plasmodium Infections / Pregnancy1
4CompletedOtherPlasmodium Infections1
4CompletedPreventionAnemias / Plasmodium Infections1
4CompletedPreventionPlasmodium Falciparum1
4CompletedScreeningPlasmodium Falciparum Malaria1
4CompletedTreatmentFalciparum / Plasmodium Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Malaria caused by Plasmodium falciparum1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Plasmodium Infections1
4CompletedTreatmentInstantaneous Clearance1
4CompletedTreatmentMalaria (Uncomplicated)1
4CompletedTreatmentMalaria caused by Plasmodium falciparum5
4CompletedTreatmentParasitologically Confirmed; Malarial1
4CompletedTreatmentPlasmodium Falciparum Malaria3
4CompletedTreatmentPlasmodium Infections17
4CompletedTreatmentPlasmodium Vivax Infection1
4CompletedTreatmentUncomplicated P. Falciparum Malaria in Children1
4Not Yet RecruitingTreatmentPlasmodium Infections1
4RecruitingTreatmentMalaria caused by Plasmodium falciparum1
4RecruitingTreatmentUncomplicated Plasmodium Falciparum Malaria1
4TerminatedTreatmentFalciparum / Plasmodium Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4TerminatedTreatmentMalaria caused by Plasmodium falciparum1
4TerminatedTreatmentMalaria caused by plasmodium vivax1
4TerminatedTreatmentPlasmodium Infections1
4Unknown StatusNot AvailableMalaria Transmission1
4Unknown StatusPreventionAnemias / Change in Sustained Attention / Helminthiasis / Plasmodium Infections / Schistosoma infection1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
4Unknown StatusTreatmentPlasmodium Infections3
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
4Unknown StatusTreatmentUncomplicated Malaria1
Not AvailableCompletedNot AvailableUncomplicated Malaria1
Not AvailableCompletedHealth Services ResearchPlasmodium Infections / Pneumonia1
Not AvailableCompletedOtherPlasmodium Infections1
Not AvailableCompletedPreventionPlasmodium Infections1
Not AvailableCompletedTreatmentAcute Non-falciparum Malaria1
Not AvailableCompletedTreatmentMalaria caused by Plasmodium falciparum2
Not AvailableCompletedTreatmentNon-malarial Febrile Illness / Plasmodium Infections1
Not AvailableCompletedTreatmentPlasmodium Infections6
Not AvailableCompletedTreatmentPlasmodium Infections / Pneumonia1
Not AvailableCompletedTreatmentPlasmodium Infections / Severe Acute Malnutrition1
Not AvailableCompletedTreatmentUncomplicated Malaria2
Not AvailableNot Yet RecruitingPreventionPlasmodium Infections1
Not AvailableTerminatedTreatmentPlasmodium Falciparum Malaria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.09e-05 mg/mLALOGPS
logP8.34ALOGPS
logP9.19ChemAxon
logS-7.2ALOGPS
pKa (Strongest Acidic)14.1ChemAxon
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity160.81 m3·mol-1ChemAxon
Polarizability60.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9363
Caco-2 permeable+0.6319
P-glycoprotein substrateSubstrate0.8389
P-glycoprotein inhibitor IInhibitor0.6854
P-glycoprotein inhibitor IINon-inhibitor0.5475
Renal organic cation transporterInhibitor0.5792
CYP450 2C9 substrateNon-substrate0.7971
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.7076
CYP450 1A2 substrateInhibitor0.6872
CYP450 2C9 inhibitorNon-inhibitor0.7112
CYP450 2D6 inhibitorInhibitor0.7727
CYP450 2C19 inhibitorNon-inhibitor0.6525
CYP450 3A4 inhibitorNon-inhibitor0.6983
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7168
Ames testNon AMES toxic0.6424
CarcinogenicityNon-carcinogens0.7629
BiodegradationNot ready biodegradable0.9924
Rat acute toxicity2.4077 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7654
hERG inhibition (predictor II)Inhibitor0.776
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as fluorenes. These are compounds containing a fluorene moiety, which consists of two benzene rings connected through either a cyclopentane, cyclopentene, or cyclopenta-1,3-diene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Fluorenes
Sub Class
Not Available
Direct Parent
Fluorenes
Alternative Parents
Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Fluorene / Chlorobenzene / Aralkylamine / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / 1,2-aminoalcohol / Tertiary aliphatic amine / Secondary alcohol
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
tertiary amine, secondary alcohol, monochlorobenzenes, fluorenes (CHEBI:156095)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da

Drug created on May 15, 2010 19:04 / Updated on November 02, 2019 01:59